drugset / Trial / NCT02170337

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

NCT02170337

Phase 1 Completed 41 enrolled Amgen
RandomizedSingle-groupQuadruple-blindTreatment

Summary

A randomized, double-blind, ascending multiple dose study in healthy volunteers and subjects with chronic rhinosinusitis with nasal polyps

Timeline

Start
2014-07
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Astegolimab Monoclonal antibody Subcutaneous